ACSS2 and plasma cell myeloma: Furthermore, elevated ACSS2 expression levels have been implicated in adverse prognostic outcomes across various malignancies including hepatic carcinoma, renal carcinoma, and multiple myeloma (Zhang et al., 2018; Wang Y. H. et al., 2019; Li Z. et al., 2021).